BACKGROUND AND PURPOSE: Two metabolites of tryptophan, 5-hydroxyindole and kynurenic acid (kynurenate) affect the function of alpha7 nicotinic acetylcholine receptors (nAChRs), as measured by electrophysiological and Ca2+ fluorescence techniques. To better understand the modulations by 5-hydroxyindole and kynurenate of the function of nAChR subtypes, we compared the effects of 5-hydroxyindole and kynurenate on the release of various transmitters evoked by nAChR activation. EXPERIMENTAL APPROACH: The function of alpha7nAChRs located on glutamatergic terminals was investigated by monitoring the release of [3H]D-aspartate or of endogenous glutamate from neocortical synaptosomes. We also comparatively considered non-alpha7 release-enhancing nAChRs localized on hippocampal noradrenergic or cholinergic terminals, as well as on striatal dopaminergic terminals. KEY RESULTS: Epibatidine or nicotine, inactive on their own on basal release, enhanced [3H]D- aspartate and glutamate efflux in presence of 5-hydroxyindole. The release evoked by nicotine plus 5-hydroxyindole was abolished by methyllycaconitine or alpha-bungarotoxin. Presynaptic nAChRs mediating the release of [3H]noradrenaline ([3H]NA), [3H]dopamine ([3H]DA), or [3H]ACh were inhibited by 5-OHi. The alpha7nAChR-mediated release of [3H]D-aspartate was reduced by kynurenate at concentrations unable to affect the non-alpha7 receptor-mediated release of tritiated NA, DA or ACh. CONCLUSIONS AND IMPLICATIONS: (i) 5-hydroxyindole permits selective activation of alpha7nAChRs mediating glutamate release; (ii) kynurenate down-regulates the permissive role of 5-hydroxyindole on alpha7nAChR activation; (iii) the non-alpha7nAChRs mediating release of NA, DA or ACh can be inhibited by 5-hydroxyindole, but not by kynurenate. These findings suggest up the possibility of developing novel drugs able to modulate selectively the cholinergic-glutamatergic transmission.
BACKGROUND AND PURPOSE: Two metabolites of tryptophan, 5-hydroxyindole and kynurenic acid (kynurenate) affect the function of alpha7 nicotinic acetylcholine receptors (nAChRs), as measured by electrophysiological and Ca2+ fluorescence techniques. To better understand the modulations by 5-hydroxyindole and kynurenate of the function of nAChR subtypes, we compared the effects of 5-hydroxyindole and kynurenate on the release of various transmitters evoked by nAChR activation. EXPERIMENTAL APPROACH: The function of alpha7nAChRs located on glutamatergic terminals was investigated by monitoring the release of [3H]D-aspartate or of endogenous glutamate from neocortical synaptosomes. We also comparatively considered non-alpha7 release-enhancing nAChRs localized on hippocampal noradrenergic or cholinergic terminals, as well as on striatal dopaminergic terminals. KEY RESULTS:Epibatidine or nicotine, inactive on their own on basal release, enhanced [3H]D- aspartate and glutamate efflux in presence of 5-hydroxyindole. The release evoked by nicotine plus 5-hydroxyindole was abolished by methyllycaconitine or alpha-bungarotoxin. Presynaptic nAChRs mediating the release of [3H]noradrenaline ([3H]NA), [3H]dopamine ([3H]DA), or [3H]ACh were inhibited by 5-OHi. The alpha7nAChR-mediated release of [3H]D-aspartate was reduced by kynurenate at concentrations unable to affect the non-alpha7 receptor-mediated release of tritiated NA, DA or ACh. CONCLUSIONS AND IMPLICATIONS: (i) 5-hydroxyindole permits selective activation of alpha7nAChRs mediating glutamate release; (ii) kynurenate down-regulates the permissive role of 5-hydroxyindole on alpha7nAChR activation; (iii) the non-alpha7nAChRs mediating release of NA, DA or ACh can be inhibited by 5-hydroxyindole, but not by kynurenate. These findings suggest up the possibility of developing novel drugs able to modulate selectively the cholinergic-glutamatergic transmission.
Authors: Edna F R Pereira; Corey Hilmas; Mariton D Santos; Manickavasagom Alkondon; Alfred Maelicke; Edson X Albuquerque Journal: J Neurobiol Date: 2002-12
Authors: A Poli; A Contestabile; P Migani; L Rossi; C Rondelli; M Virgili; R Bissoli; O Barnabei Journal: J Neurochem Date: 1985-12 Impact factor: 5.372
Authors: Manickavasagon Alkondon; Edna F R Pereira; Ping Yu; Emerson Z Arruda; Luis E F Almeida; Paolo Guidetti; William P Fawcett; Michael T Sapko; William R Randall; Robert Schwarcz; Danilo A Tagle; Edson X Albuquerque Journal: J Neurosci Date: 2004-05-12 Impact factor: 6.167
Authors: Nicolas Champtiaux; Cecilia Gotti; Matilde Cordero-Erausquin; Denis J David; Cédric Przybylski; Clément Léna; Francesco Clementi; Milena Moretti; Francesco M Rossi; Nicolas Le Novère; J Michael McIntosh; Alain M Gardier; Jean-Pierre Changeux Journal: J Neurosci Date: 2003-08-27 Impact factor: 6.167
Authors: Outi Salminen; Karen L Murphy; J Michael McIntosh; John Drago; Michael J Marks; Allan C Collins; Sharon R Grady Journal: Mol Pharmacol Date: 2004-06 Impact factor: 4.436
Authors: Michelle C Potter; Greg I Elmer; Richard Bergeron; Edson X Albuquerque; Paolo Guidetti; Hui-Qiu Wu; Robert Schwarcz Journal: Neuropsychopharmacology Date: 2010-03-24 Impact factor: 7.853
Authors: Hui-Qiu Wu; Edna F R Pereira; John P Bruno; Roberto Pellicciari; Edson X Albuquerque; Robert Schwarcz Journal: J Mol Neurosci Date: 2009-08-19 Impact factor: 3.444
Authors: Gretchen Y López-Hernández; Jeffrey S Thinschmidt; Philippe Morain; Caryn Trocme-Thibierge; William R Kem; Ferenc Soti; Roger L Papke Journal: Neuropharmacology Date: 2009-03 Impact factor: 5.250